Figure 4.
Expression of the SIRT1 in osteoblasts of different groups. (A) Expression of SIRT1 mRNA in osteoblasts treated with increasing concentrations of resveratrol (0 M, 10−8 M, 10−7 M, 10−6 M), as assessed with quantitative real-time polymerase chain reaction (RT-PCR). (B) Expression of SIRT1 in osteoblasts treated with resveratrol (50 µM) for 0, 5, 30, 60, 120 min, as assessed with Western blot. (C) Confocal immunofluorescence (IF) staining of osteoblasts with or without resveratrol stained for SIRT1 (red). Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). The intensity of SIRT1 was higher in serum-starved osteoblasts cells cultured in serum-free medium with resveratrol. (D) Expression of SIRT1 protein in osteoblasts among different groups, as assessed with Western blot. (E) BrdU and MTT assays for proliferation and viability of osteoblasts that were treated with or without dexamethasone, with or without resveratrol and NAM. Analysis of the proliferation and viability of osteoblasts with different treatments as assessed with the BrdU assays and the MTT assay. The figures represent three independent experiments. Asterisks indicate significant differences compared to the control group (*P < 0.05).